Talor Sax

Our cutting-edge technology provides medical professionals with real-time monitoring of renal output, a crucial vital sign that aids in the assessment of a patients hemodynamic status in various clinical settings, including operating rooms and critical care units. By utilizing our solution, healthcare providers detect and address potential complications promptly, reducing hospitalization-related complications and saving lives.

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the worlds first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

Yonalink provides EHR-to-EDC streaming and AI-driven CRF mapping along with other clinical trial data management solutions. Yonalink eliminates the manual work involved in clinical data capture to guarantee secure, error-free data collection from EHR to EDC. By collecting and transfering clinical trial data in real-time, Yonalink improves trial efficiency and data quality, reduces medical center staff burnout, and provides wider access to novel patient care opportunities.

AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide, by preventing the next heart attack. AccuLine is developing CORA— a smart, accurate, and easy to use exam for the early detection of coronary artery disease. The clinically validated CORA deploys advanced ML-powered signal processing algorithms, analyzing two bio-signals the company discovered in the heart’s electrical activity, indicating the patient’s risk of having coronary artery disease. AccuLine has received a grant from the Israeli Innovation Authority and is a portfolio company of eHealth Ventures—founded by Maccabi Health Services, backed by Amgen, Medison Ventures, SCI (Shanghai Creation Investment), and partnered with Mayo Clinic.

First non-contact telediagnostic IOP measurement device technology

Olive Diagnostics has developed a 100% passive sensor which is able to provide real time health alerts, early detection and progression of diseases. The device can be used for self monitoring or remote monitoring of loved ones. Using optics as a source of data collection, the sensor is mounted into the toilet and doesnt require any intervention. Users urinate in the toilet the same way they have all their lives, and the urine is monitored and analysed for any changes or abnormatlities. Monitor the following biomarkers: Hydration Pregnancy Ovulation RBC (early detection of Kidney Stones) WBC (UTI) Protein (Preeclamsia, Infections) Electrolytes (Dis balance) Changes in Urination Patterns (volume, time of day, frequency, duration) Glucose, Ketone, Protein (Diabetes, pre-Diabetes) Ketone - (dietary and starvation) Specific Gravity ( Hepathrenal syndrom) And this is just the tip of the iceberg.... The passiveness of the device makes it perfect for tracking a person’s bodily functions, keeping it healthy always.

Nervio is a digital health startup in the field of intraoperative neuromonitoring, building the world’s first autonomous AI neuromonitoring solution to prevent avoidable paralysis and severe neurologic complications. Its AI-powered solution alerts clinicians in real-time to any neurological complications right in the operating room, thus minimizing permanent nerve injuries.

Helping people with complex pain syndromes unlock the potential of neuroplasticity training. TrainPain's early access program is now open for people with CRPS. Visit our website to learn more.

We designed a portable, affordable and easy to use hematology lab, which provides instant results like CBC, complete blood count. The platform technology houses multiple clinical applications and has an AI based microscope. It reduces cost, time and it improves the doctor-patient experience. EFA brings the LAB to the BLOOD and not the BLOOD to the LAB without the need for an expert preparation. EfA is changing the diagnostics paradigm step by step by enabling tests which were ONLY available in the labs/clinics/hospitals etc. to be done ANYTIME and EVERYWHERE. An early and rapid diagnostic is a key to the prevention of overuse and improper medications. Many millions of people cannot access a proper diagnostic due to their medical condition and/or where they live. Bringing as many as possible medical services closer to them, will make a huge impact on how we manage health around the world. The initial application of a complete blood count everywhere will give results in less than 5 minutes ON THE DEVICE. EfA also creates a marketplace for developers, partners and researches adding health-apps for various conditions and future diagnostic needs. EfA's RevDx portable device realtime analysis enables telemedicine applications.

SpeakSuite is a groundbreaking speech therapy platform designed to help children who are struggling with articulation and generalization. Developed by speech-language pathologists, sound-recognition experts, and software engineers, SpeakSuite gives SLPs powerful new tools to make articulation therapy more fun and more effective, and gives kids exciting new ways to practice at home.

Intendu is a digital health company delivering software for brain training targeted at people with brain dysfunction. Intendu's mission is to provide effective and affordable cognitive training to everyone who needs it, everywhere. Intendu was founded by neuroscientists and develops solutions for patients and clinicians.

Our cutting-edge technology provides medical professionals with real-time monitoring of renal output, a crucial vital sign that aids in the assessment of a patients hemodynamic status in various clinical settings, including operating rooms and critical care units. By utilizing our solution, healthcare providers detect and address potential complications promptly, reducing hospitalization-related complications and saving lives.

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the worlds first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

Yonalink provides EHR-to-EDC streaming and AI-driven CRF mapping along with other clinical trial data management solutions. Yonalink eliminates the manual work involved in clinical data capture to guarantee secure, error-free data collection from EHR to EDC. By collecting and transfering clinical trial data in real-time, Yonalink improves trial efficiency and data quality, reduces medical center staff burnout, and provides wider access to novel patient care opportunities.

Amidst adversity, opportunity unfolds. The ongoing conflict has cast a challenging shadow over Israels dynamic startup landscape, particularly impacting promising seed-stage enterprises. These ventures, the bedrock of our economic future, face unprecedented vulnerability, grappling with funding hurdles and unpredictable delays during these tumultuous times. 10 distinguished incubators have united in purpose and mission. Our portfolio companies, once on the brink of success, growth, and securing essential funding, now find themselves amidst unforeseen adversity. Together, we stand resolute, dedicated to reinstating their path to success.

AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide, by preventing the next heart attack. AccuLine is developing CORA— a smart, accurate, and easy to use exam for the early detection of coronary artery disease. The clinically validated CORA deploys advanced ML-powered signal processing algorithms, analyzing two bio-signals the company discovered in the heart’s electrical activity, indicating the patient’s risk of having coronary artery disease. AccuLine has received a grant from the Israeli Innovation Authority and is a portfolio company of eHealth Ventures—founded by Maccabi Health Services, backed by Amgen, Medison Ventures, SCI (Shanghai Creation Investment), and partnered with Mayo Clinic.